

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

**1. – 8. (Canceled)**

**9. (Currently Amended)** A method for treating ~~the~~ an inflammatory component of a disease selected from cystic fibrosis, idiopathic lung fibrosis and fibrosing alveolitis, which method comprises administering, via inhalation, a formulation comprising an active substance which consists of a therapeutically effective amount of a salt of tiotropium, and, optionally, physiologically acceptable excipients.

**10. (Canceled)**

**11. (Currently Amended)** The method as recited in claim 9 wherein ~~the anion of~~ the tiotropium salt ~~is~~ has an anion selected from chloride, bromide, iodide, methanesulphonate, paratoluenesulphonate and methylsulphate.

**12. (Previously presented)** The method as recited in claim 11 wherein the anion of the tiotropium salt is methanesulphonate, chloride, bromide or iodide.

**13. (Previously presented)** The method as recited in claim 12 wherein the anion of the tiotropium salt is methanesulphonate or bromide.

**14. (Previously presented)** The method of claim 9, wherein the salt of tiotropium is administered via inhalation in a formulation selected from powders for inhalation, metered-dose aerosols containing propellant gas and propellant-gas-free inhalable solutions.

**15. (Previously presented)** The method of claim 14, wherein the formulation is an inhalable powder which contains the tiotropium salt in admixture with a suitable physiologically acceptable excipient selected from monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, and mixtures thereof.

**16. (Previously presented)** The method of claim 14, wherein the formulation is an inhalable aerosol containing a propellant gas, which contains the tiotropium salt in dissolved or dispersed form.

- 17. (Previously presented)** The method of claim 16, wherein the propellant gas is a hydrocarbon or halohydrocarbon gas.
- 18. (Previously presented)** The method of claim 16, wherein the propellant gas is n-butane, isobutane, or a fluorinated methane, ethane, propane, butane, cyclopropane or cyclobutane.
- 19. (Previously presented)** The method of claim 16, wherein the propellant gas is TG134a, TG227 or a mixture thereof.
- 20. (Previously presented)** The method of claim 16, wherein the inhalable aerosol further comprises one or more other ingredients selected from co-solvents, stabilizers, surfactants, antioxidants, lubricants and pH adjusters.
- 21. (Previously presented)** The method of claim 14, wherein the formulation is a propellant-free inhalable solution which further comprises a solvent selected from water, ethanol or a mixture of water and ethanol.
- 22. (Previously presented)** The method of claim 21, wherein the pH of the propellant-free inhalable solution is 2 - 7.
- 23. (Previously presented)** The method of claim 21, wherein the propellant-free inhalable solution further comprises a co-solvent which contains hydroxyl groups or other polar groups.
- 24. (Canceled)**
- 25. (Previously presented)** The method of claim 23, wherein the cosolvent is an alcohol or glycol.
- 26. (Previously presented)** The method of claim 23, wherein the propellant-free inhalable solution further comprises at least one surfactant, stabilizer, complexing agent, antioxidant, preservative, flavoring, pharmacologically acceptable salt or vitamin.
- 27. (Previously presented)** The method of claim 14, wherein the formulation further comprises, as complexing agent, editic acid or a salt of editic acid.

- 28. (Previously presented)** The method of claim 14, wherein the formulation further comprises, as complexing agent, sodium edetate.
- 29. (Previously presented)** The method of claim 21, wherein the propellant-free inhalable solution contains only benzalkonium chloride and sodium edetate in addition to the active substance and the solvent.
- 30. (Previously presented)** The method of claim 21, wherein the propellant-free inhalable solution is a concentrate or a sterile inhalable solution ready for use.
- 31. (Previously presented)** The method as recited in claim 12 wherein the anion of the tiotropium salt is bromide.
- 32. (Previously presented)** The method of claim 9, wherein the disease treated is cystic fibrosis.